Tokumura T, Tsushima Y, Tatsuishi K, Kayano M, Machida Y, Nagai T
J Pharm Sci. 1987 Apr;76(4):286-8. doi: 10.1002/jps.2600760404.
The present study was an attempt to develop a new dosage form of cinnarizine, which is slightly soluble in water, using lipid as a vehicle. The solubility of cinnarizine in several organic solvents was determined. It was found that cinnarizine dissolved well in oleic and linoleic acids. The bioavailability of cinnarizine from the oral administration of an oleic acid solution in a hard capsule was investigated and compared with that of a cinnarizine tablet, using beagle dogs. When cinnarizine was administered in a capsule, the bioavailability was greatly enhanced [i.e., the maximum concentration (Cmax) and AUC values were 2.9 and 4.0 times larger than those of a cinnarizine tablet, respectively]. Meanwhile, the tmax value (the time to reach Cmax) was unchanged. The absorption of cinnarizine from an oleic acid solution was considered to depend on the action of bile salts. This was supported by the results of a dissolution test using a bile salts solution as the dissolution test medium.
本研究试图以脂质为载体开发一种新的桂利嗪剂型,桂利嗪在水中微溶。测定了桂利嗪在几种有机溶剂中的溶解度。发现桂利嗪在油酸和亚油酸中溶解良好。使用比格犬研究了硬胶囊中油酸溶液口服给药后桂利嗪的生物利用度,并与桂利嗪片剂进行了比较。当桂利嗪以胶囊形式给药时,生物利用度大大提高[即,最大浓度(Cmax)和AUC值分别比桂利嗪片剂大2.9倍和4.0倍]。同时,达峰时间(tmax)值(达到Cmax的时间)没有变化。认为桂利嗪从油酸溶液中的吸收取决于胆盐的作用。以胆盐溶液作为溶出试验介质的溶出试验结果支持了这一点。